These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 25683992

  • 1. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW, Oh M, Sin JB.
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [Abstract] [Full Text] [Related]

  • 2. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S.
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A, Allen R, Doros G, O'Brien S.
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G, Kanmaz Kutman HG, Canpolat FE, Oğuz ŞS.
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G, Lacaze-Masmonteil T, Neonatologists of the Curosurf Postmarketing French Study.
    Paediatr Drugs; 2003 Mar; 5(9):639-45. PubMed ID: 12956620
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K, North American Study Group.
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [Abstract] [Full Text] [Related]

  • 12. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Ramanathan R, Bhatia JJ, Sekar K, Ernst FR.
    J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Choosing a right surfactant for respiratory distress syndrome treatment.
    Ramanathan R.
    Neonatology; 2009 Feb; 95(1):1-5. PubMed ID: 18832858
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
    Malloy CA, Nicoski P, Muraskas JK.
    Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Complications among premature neonates treated with beractant and poractant alfa.
    Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F.
    Indian J Pediatr; 2010 Jul; 77(7):751-4. PubMed ID: 20589459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.